- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00286962
Study to Compare Intraperitoneal Insulin to Subcutaneous Insulin Administration in Type 1 Diabetes Mellitus
A Randomized Cross-Over Single Centre Study Comparing the Effects of Intraperitoneal Insulin Administration to Subcutaneous Insulin Administration in Type 1 Diabetes Mellitus Patients
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Various study data available suggest that intraperitoneal (IP) delivery of insulin in type 1 and type 2 diabetic subjects provides an appropriate therapy that allows subjects to achieve acceptable glycemic control without increasing the inherent risk of severe hypoglycemia observed when intensive insulin treatment is pursued. Up till now little research has been done to investigate the efficacy of intraperitoneal (IP) therapy compared to subcutaneous administration. In this study we aim for safety and non-inferiority or superiority for IP therapy concerning glycemic control with less episodes of hypoglycemia compared to intensive subcutaneous (SC) therapy in intermediate or poorly controlled Type 1 patients and/or patients with frequent severe hypoglycemic events.
Subjects will be randomized to insulin treatment using the Medtronic Minimed Implantable Pump or to subcutaneous insulin therapy during the first study arm. After the first arm of the study, subjects will be crossed over to the second arm and will receive the treatment whichever they had not received in the first treatment phase. Subjects with the MIP already implanted will retain the pump but will receive diluent intraperitoneally for the second study arm.
Study Type
Enrollment (Actual)
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
-
Zwolle, Netherlands, 8000 GM
- Isala Klinieken
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Type 1 diabetes mellitus
- Intermediate or poor glycemic control, defined as HbA1c ≥ 7,5% AND/OR ≥ 5 incidents of hypoglycemia a week.
Exclusion Criteria:
- renal function impairment: creatinin ≥ 150 micromol/L or a creatinin clearance < 50 ml/min
- Cardiac problems: decompensated heart failure (NYHA III and IV); diagnosis of unstable angina pectoris; myocardial infarction within the last 12 months
- Known or suspected allergy against insulin or any component of the composition
- Mental retardation or psychiatric treatment for schizophrenia, organic mental disorder or bipolar disorder currently or in the past.
- Severe untreated proliferative retinopathy.
- Insufficient knowledge of the Dutch language to understand the requirements of the study.
- Current use of systemic corticosteroids or suffering from a condition which caused systemic corticosteroid use more than once in the last year.
- Substance abuse, other than nicotine
- A history of cancer, excluding well differentiated thyroid carcinoma, breast carcinoma without lymph node metastases and skin carcinoma
- Participation in other trials, involving investigational products within 30 days prior to trial entry.
- Plans to engage in activities which require them to go below 25 feet below sea level.
- Any condition that the Investigator and/or Coordinating Investigator feels would interfere with trial participation or evaluation of results.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: CIPII
Intraperitoneal insulin infusion by means of an implanted insulin pump
|
Intraperitoneal insulin infusion delivered by an implantable pump: MIP 2007c
|
Active Comparator: CSII/ MDI
Optimized subcutaneous insulin infusion by means of continuous subcutaneous insulin infusion (CSII) or by multiple daily injections (MDI)
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
---|
incidence of hypoglycemia; data taken from patient diaries during either study arm.
|
Secondary Outcome Measures
Outcome Measure |
---|
glycemic control; glycosylated hemoglobin (HbA1c) measurement at baseline, end of entry phase, start of both study arms, halfway through study arms, end of study arms.
|
average daily insulin usage; as taken from patient diaries for both study arms
|
frequency of adverse events; as taken from patient diaries for both study arms
|
frequency of clinically significant abnormal laboratory values and device complications; as taken from patient diaries for both study arms
|
Quality of life; score on a quality of life scale at baseline and end of either study arm
|
Treatment satisfaction; score on treatment satisfaction scale at baseline and end of either study arm
|
daily glucose excursions; measured with continuous glucose monitoring system (CGMS) at baseline, halfway through and at the end of both study arms
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Henk J Bilo, MD, PhD, Isala clinics, medical research foundation
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- IC-06-01-SL
- 04.0211p
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Diabetes Mellitus, Type 1
-
SanofiCompletedType 1 Diabetes Mellitus-Type 2 Diabetes MellitusHungary, Russian Federation, Germany, Poland, Japan, United States, Finland
-
University of Colorado, DenverMassachusetts General Hospital; Beta Bionics, Inc.CompletedDiabetes Mellitus, Type 1 | Type 1 Diabetes | Diabetes type1 | Type 1 Diabetes Mellitus | Autoimmune Diabetes | Diabetes Mellitus, Insulin-Dependent | Juvenile-Onset Diabetes | Diabetes, Autoimmune | Insulin-Dependent Diabetes Mellitus 1 | Diabetes Mellitus, Insulin-Dependent, 1 | Diabetes Mellitus, Brittle | Diabetes Mellitus, Juvenile-Onset and other conditionsUnited States
-
University of California, San FranciscoJuvenile Diabetes Research FoundationCompletedType 1 Diabetes Mellitus | Diabetes Mellitus, Type I | Insulin-Dependent Diabetes Mellitus 1 | Diabetes Mellitus, Insulin-Dependent, 1 | IDDMUnited States, Australia
-
AstraZenecaCompletedType 2 Diabetes Mellitus | Type 1 Diabetes MellitusUnited States
-
Capillary Biomedical, Inc.TerminatedType 1 Diabetes | Type 1 Diabetes Mellitus | Diabetes Mellitus, Type I | Diabetes Mellitus, Insulin-Dependent, 1 | IDDMAustria
-
National Institute of Allergy and Infectious Diseases...PPD; Rho Federal Systems Division, Inc.; Immune Tolerance Network (ITN)CompletedType 1 Diabetes Mellitus | T1DM | T1D | New-onset Type 1 Diabetes MellitusUnited States, Australia
-
Shanghai Changzheng HospitalRecruitingBrittle Type 1 Diabetes MellitusChina
-
Capillary Biomedical, Inc.CompletedDiabetes Mellitus, Type 1 | Type 1 Diabetes | Type 1 Diabetes Mellitus | Diabetes Mellitus, Insulin-Dependent, 1Australia
-
Spiden AGDCB Research AGRecruitingType 1 Diabetes Mellitus | Type 1 Diabetes Mellitus With Hypoglycemia | Type 1 Diabetes Mellitus With HyperglycemiaSwitzerland
-
Hoffmann-La RocheRoche DiagnosticsCompletedDiabetes Mellitus Type 2, Diabetes Mellitus Type 1Germany
Clinical Trials on MIP 2007C implantable insulin pump
-
Medtronic DiabetesCompletedType 1 DiabetesUnited States
-
Codman & ShurtleffCompletedChronic PainGermany, France, United Kingdom
-
Institut Cancerologie de l'OuestCompletedAdvanced Cancer | Intractable PainFrance
-
Nuwellis, Inc.Terminated
-
NiliMedixCompletedDiabetes MellitusIsrael
-
Medtronic DiabetesCompletedDiabetes Mellitus, Type 1Netherlands, Slovenia, Denmark, Austria, Italy, Luxembourg, Spain
-
Hoffmann-La RocheCompleted
-
Medtronic DiabetesCompletedType 1 DiabetesUnited States
-
Boston Children's HospitalCompletedType 1 Diabetes MellitusUnited States
-
Cerebral Therapeutics LLCTerminated